These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and now is deepening the foothold of its first commercial product Besremi.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…
